Study of a new drug for advanced ovarian cancer that stopped responding to platinum
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a new drug called SYS6043 for advanced ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. It aims to see if this drug can help when other treatments have not worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and female.
- You have a type of ovarian, fallopian tube, or primary peritoneal cancer called high-grade serous or G2-G3 endometrioid carcinoma.
- Your cancer has progressed or come back within 6 months after your last platinum-based chemotherapy, and you have had 5 or fewer lines of treatment in total.
- You have at least one tumor that can be measured on a scan.
- You are generally well (able to do light activity) and have a life expectancy of at least 3 months.
- You are willing to provide a past or new tumor sample for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HS-20089, for people with ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
This study tests a new drug called SHR-A1921 for people with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
This trial tests a new drug, SYS6043, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help shrink or control the tumor.
This trial tests if adding the drug IN10018 to standard chemotherapy (liposomal doxorubicin) can help women with ovarian cancer that has stopped responding to platinum-based treatments. It aims to see if the combination works better than chemotherapy alone.
This study tests a new drug called SYS6043, alone or with other treatments, for advanced solid tumors that have not responded to standard therapy. It may offer a new option for patients with certain types of ovarian, fallopian tube, or primary peritoneal cancer.
This study tests a new investigational drug called JSKN003 for people with ovarian cancer that has stopped responding to standard chemotherapy. The goal is to see if this drug can help shrink tumors and slow down the cancer's growth.
Hear when a new Platinum-resistant Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.